Alamo’s Sales Slide and EPS Pressure Might Change The Case For Investing In Alamo Group (ALG)

Alamo Group Inc.

Alamo Group Inc.

ALG

0.00

  • Alamo Group recently reported that over the last two years it has faced a 2.6% annual sales decline and falling earnings per share, alongside sluggish projected sales growth in its core vegetation management and infrastructure equipment markets.
  • This deterioration in sales and earnings quality has sharpened investor focus on whether the company’s current valuation and business mix can withstand a tougher cycle for its equipment end-markets.
  • We’ll now examine how concerns about Alamo Group’s declining sales and earnings may reshape the earlier investment narrative built around margin resilience and growth.

Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

Alamo Group Investment Narrative Recap

To own Alamo Group today, you need to believe its niche in vegetation management and infrastructure equipment remains durable enough to justify paying about 16.6x forward earnings, even after a 2.6% annual sales decline and weaker EPS. The recent results highlight that the key near term catalyst is now evidence of stabilizing demand in its core markets, while the biggest immediate risk is that a soft equipment cycle keeps pressuring margins and earnings. If that risk does not worsen, the longer term thesis is largely intact.

The most relevant recent announcement is the fourth quarter and full year 2025 earnings release, which showed lower sales and EPS versus the prior year and effectively confirmed the deterioration now in focus. These results sit in tension with earlier optimism around margin resilience and backlog strength, and they raise the bar for upcoming quarters to show that Alamo can translate its government and infrastructure exposure into steadier earnings before investors regain confidence in the prior growth narrative.

But investors should be aware that Alamo’s heavy reliance on government and contractor equipment spending could quickly become a headwind if...

Alamo Group's narrative projects $1.8 billion revenue and $169.3 million earnings by 2029. This requires 4.1% yearly revenue growth and about a $65.5 million earnings increase from $103.8 million today.

Uncover how Alamo Group's forecasts yield a $207.40 fair value, a 21% upside to its current price.

Exploring Other Perspectives

ALG 1-Year Stock Price Chart
ALG 1-Year Stock Price Chart

Two members of the Simply Wall St Community currently place Alamo Group’s fair value between US$196.89 and US$207.40, highlighting how individual views can differ even in a tight range. When you set those estimates against the recent sales and EPS declines, it underlines why some investors are now weighing the risk that prolonged weakness in government and contractor demand could keep earnings under pressure and why it can be useful to compare several different viewpoints side by side.

Explore 2 other fair value estimates on Alamo Group - why the stock might be worth as much as 21% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Alamo Group research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • Our free Alamo Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alamo Group's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

  • Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
  • Find 53 companies with promising cash flow potential yet trading below their fair value.
  • AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.